Brachytherapy
Volume 6, Issue 4 , Pages 258-266 , October 2007

The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy

  • Nathan Bittner

      Affiliations

    • Department of Radiation Oncology, University of Washington, Seattle, WA
    • ,
  • Gregory S. Merrick

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • Corresponding Author InformationCorresponding author. The Schiffler Cancer Center, Wheeling Hospital, 1 Medical Park, Wheeling, WV 26003. Tel.: +1-304-243-3490; fax: +1-304-243-5047.
    • ,
  • Kent E. Wallner

      Affiliations

    • Department of Radiation Oncology, University of Washington, Seattle, WA
    • Radiation Oncology, Puget Sound Health Care System, Department of Veterans Affairs, Seattle, WA
    • ,
  • Jonathan H. Lief

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • ,
  • Wayne M. Butler

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV
    • ,
  • Robert W. Galbreath

      Affiliations

    • Schiffler Cancer Center and Wheeling Jesuit University, Wheeling, WV

Received 7 May 2007 ,Revised 15 August 2007 ,Accepted 24 August 2007.

References 

  1. Stone N, Stock R, Unger P. Intermediate term biochemical-free progression and local control following 125-I brachytherapy for prostate cancer. J Urol. 2005;173:803–807
  2. Zelefsky M, Wallner K, Ling C, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostate cancer. J Clin Oncol. 1999;17:517–522
  3. Davis J, Kuban D, Lynch D, et al. Quality-of-life after treatment for localized prostate cancer: Differences based on treatment modality. J Urol. 2001;166:947–952
  4. Merrick GS, Butler WM, Lief J, et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;47:121–128
  5. Merrick G, Butler W. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation. Tech Urol. 2000;6:78–84
  6. Wallner K, Roy J, Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1995;32:465–471
  7. Allen ZA, Merrick GS, Butler WM, et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys. 2005;62:981–987
  8. Wallner K, Merrick G, True L, et al. I-125 versus Pd-103 for low-risk prostate cancer: Morbidity outcomes for a prospective randomized multicenter trial. Cancer J. 2002;8:67–73
  9. Niehaus A, Merrick GS, Butler WM, et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64:136–143
  10. Beekman M, Merrick GS, Butler WM, et al. Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorable influence brachytherapy-related urinary morbidity. Urology. 2005;66:1266–1270
  11. Merrick GS, Butler WM, Wallner KE, et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol. 2003;26:E178–E189
  12. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995;22:209–234
  13. Merrick GS, Butler WM, Dorsey AT, et al. Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys. 2000;46:215–220
  14. Merrick GS, Butler WM, Wallner KE, et al. Dysuria after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;55:979–985
  15. Butler WM, Merrick GS, Dorsey AT, et al. Comparison of dose length, area, and volume histograms as quantifiers of urethral dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;48:1575–1582
  16. Herstein A, Wallner KE, Merrick GS, et al. I-125 versus Pd-103 for low-risk prostate cancer: Long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J. 2005;11:385–389
  17. Merrick G, Butler W, Wallner K, et al. Long-term urinary quality of life following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;56:454–461
  18. Wallner K, Merrick G, True L, et al. 125I versus 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys. 2003;57:1297–1303
  19. Stock N, Stone R. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. Brachytherapy. 2003;2:32–39
  20. Kollmeier M, Stock R, Cesaretti J, et al. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol. 2005;173:808–812
  21. Merrick G, Butler W, Wallner K, et al. Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2004;58:81–88

PII: S1538-4721(07)00247-4

doi: 10.1016/j.brachy.2007.08.008

Brachytherapy
Volume 6, Issue 4 , Pages 258-266 , October 2007

Article Tools

* Image Usage & Resolution